Beta Pharma Inc. has presented 1,5-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) and/or (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
Programmed cell death protein 1 (PD-1) is among the immune checkpoint molecules better explored in immunotherapy for cancer. However, it is necessary to obtain novel therapies where preclinical efficacy and safety data could translate into enhanced predictability of human efficacy, pharmacokinetics and side effects.
Georgiamune Inc. has gained FDA clearance for its IND application for GIM-531, a first-in-class oral regulatory T cell (Treg) inhibitor that enables the restoration of a strong immune response against cancer.
The maintenance of mitochondrial homeostasis plays a crucial role in tumor cell survival and growth. Mitochondrial integrity is regulated by proteins in the mitochondrial inner membrane, such as prohibitin (PHB). PHB has been found overexpressed in several cancer types and contributes to tumorigenesis.
Chinese investigators have reported that high levels of triggering receptor expressed on myeloid cells 2 (TREM2) expression, which are immunosuppressive in multiple solid tumors, were protective in glioblastoma multiforme (GBM). The findings were published May 23, 2024, in Cancer Cell.
Roivant Discovery Inc. has disclosed PROTACs (proteolysis targeting chimeras) comprising an E3 ubiquitin ligase binding moiety covalently linked to an E3 ubiquitin-protein ligase Mdm2 (Hdm2)-targeting moiety through a linker.
Enliven Therapeutics Inc. has identified naphthyridine compounds acting as Raf kinase inhibitors and reported to be useful for the treatment of cancer.
A group of scientists from Basel University Hospital have designed an antibody-drug conjugate (ADC) that eliminated blood cancer cells without attacking healthy hematopoietic stem cells (HSCs), which they modified by base editing and transplanted to renew an altered blood system. They achieved this by focusing on the panhematopoietic marker CD45.
Scientists at Hansoh Bio LLC, Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising HER3 (erbB3)-targeting antibodies linked to a cytotoxic drug through a linker.
RSS
